| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe |
NCT01939496: Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents |
|
|
| Completed | 4 | 171 | US | Canagliflozin, Placebo | Janssen Scientific Affairs, LLC | Diabetes Mellitus, Type 2, Hypertension | 04/15 | 04/15 | | |
NCT02220920: Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 146 | Japan | Canagliflozin (TA-7284), Placebo, Insulin | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 07/15 | 07/15 | | |
NCT02025907 / 2013-004819-40: A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin |
|
|
| Completed | 4 | 218 | US, Canada, Europe, RoW | Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 09/15 | 09/15 | | |
NCT02227849: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 71 | Japan | Canagliflozin (TA-7284), GLP-1 analogue | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 03/16 | 03/16 | | |
NCT02622113: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 139 | Japan | Canagliflozin (TA-7284), Insulin | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 04/16 | 04/16 | | |
| Completed | 4 | 5813 | Canada, US, Europe, RoW | Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg | Janssen Research & Development, LLC, The George Institute for Global Health, Australia | Diabetes Mellitus, Type 2, Albuminuria | 02/17 | 02/17 | | |
|
|
I-Can, NCT02597309: The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin |
|
|
| Withdrawn | 4 | 0 | US | Canagliflozin, Invokana | Joslin Diabetes Center | Diabetes, Obesity | 07/17 | 07/17 | | |
NCT02360774: Mechanisms of Weight Loss With SGLT2 Inhibition |
|
|
| Completed | 4 | 30 | US | Canagliflozin, Invokana, Placebo | Beth Israel Deaconess Medical Center, Janssen Scientific Affairs, LLC | Type 2 Diabetes, Overweight, Obesity | 08/18 | 08/18 | | |
